SLC22A2 and oculocerebrorenal syndrome: Disease model: renal lithiasis (Wei et al., 2012), renal interstitial fibrosis (Zhou et al., 2014), Lowe syndrome (Naik et al., 2021); drug nephrotoxicity test: cisplatin (Jang et al., 2013; Vormann et al., 2021), tenofovir (Vormann et al., 2021), tobramycin (Vormann et al., 2021), cyclosporine A (Vormann et al., 2021), gentamicin (Ioannidis et al., 2022), polymyxin B (Jing et al., 2022), adriamycin (Jing et al., 2022) and sunitinib (Jing et al., 2022); transporter study: P-glycoprotein (Vriend et al., 2018), MRP2/4 (Vriend et al., 2018), OCT2 (Nieskens et al., 2020)